(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $2.22
Utstedt: 14 feb 2024 @ 15:33
Avkastning: -4.95%
Forrige signal: feb 13 - 21:01
Forrige signal:
Avkastning: 1.14 %
Live Chart Being Loaded With Signals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...
Stats | |
---|---|
Dagens volum | 231 237 |
Gjennomsnittsvolum | 498 904 |
Markedsverdi | 188.91M |
EPS | $0 ( 2024-03-05 ) |
Neste inntjeningsdato | ( $-0.100 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.05 |
ATR14 | $0.00500 (0.24%) |
Volum Korrelasjon
Compugen Ltd Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
ENTG | 0.933 |
ADSE | 0.932 |
KOPN | 0.93 |
CTIC | 0.926 |
RMBL | 0.917 |
ALR | 0.916 |
MVIS | 0.914 |
MRAM | 0.913 |
NWLI | 0.912 |
ORGO | 0.912 |
10 Mest negative korrelasjoner | |
---|---|
ULTA | -0.945 |
SBNYP | -0.915 |
HOLUU | -0.904 |
EMBCV | -0.899 |
TTCF | -0.889 |
OPTN | -0.888 |
CDAK | -0.884 |
CPRX | -0.88 |
PHCF | -0.87 |
BNIXU | -0.87 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Compugen Ltd Korrelasjon - Valuta/Råvare
Compugen Ltd Økonomi
Annual | 2023 |
Omsetning: | $33.46M |
Bruttogevinst: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2023 |
Omsetning: | $33.46M |
Bruttogevinst: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2022 |
Omsetning: | $7.50M |
Bruttogevinst: | $6.53M (87.00 %) |
EPS: | $-0.390 |
FY | 2021 |
Omsetning: | $6.00M |
Bruttogevinst: | $5.32M (88.67 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.